iPS Cells & Regenerative Medicine– category –
-
Intellia Therapeutics Advances CRISPR Gene Editing: Lonvo-z Achieves Phase 3 Success for HAE, Targeting Mid-2027 U.S. Launch; Nex-z Phase 3 Enrollment Resumes for ATTR
Intellia Therapeutics, Inc. (Press Release) USA Overview Intellia Therapeutics reported positive Phase 3 results for lonvo-z in hereditary angioedema (HAE), with a Biologics License Application (BLA) submission to the FDA planned for H2 ... -
iPS Cells & Regenerative Medicine Weekly Report August 9, 2026
▼ ▼ ▼ If the infographic makes you want to read the full report, please click the download button below. ▼ ▼ ▼ 📄 Weekly Report August 09, 2026 (PDF) — Download Weekly Report August 09, 2026 (PDF) — DownloadDownload 🎙 Podcast Aug... -
Lineage Cell Therapeutics Continues Support for Roche/Genentech’s OpRegen Cell Therapy, AlloSCOPE™ Platform Enables Scalable Manufacturing
Business Wire USA Overview Lineage Cell Therapeutics reported Q2 2026 financial results and business updates, confirming continued support for its OpRegen cell therapy development collaboration with Roche and Genentech, including technic... -
CAR-T Cell Therapy Established for Specific B-Cell Lymphomas/Leukemias, but Product Differentiation and Individualized Adaptation Crucial
Regenex Asia Singapore Overview CAR-T cell therapy is firmly established for specific B-cell lymphomas and leukemias, but its clinical utility hinges on aligning individual products with appropriate disease settings due to varying target... -
Cell Therapy Clinical Success Hinges on Manufacturability: Limitations of Autologous Therapies Drive Interest in Allogeneic ‘Off-the-Shelf’ Platforms
Cell & Gene Unknown Overview Cell therapy scalability is a critical factor to consider from early development, as autologous therapies face challenges in manufacturing complexity, scheduling constraints, and inherent scalability limitati... -
EVERSANA Selected as Commercialization Partner for Innovacell Inc.’s Novel Cell Therapy ICEF15 for Urgent Fecal Incontinence in the United States
Outsourced Pharma USA Overview EVERSANA has been chosen by Tokyo-based biotechnology firm Innovacell Inc. as its exclusive commercialization partner in the United States. This partnership aims to advance regenerative medicine and cell th... -
China’s First Approved MSC Therapy, Ruibosheng, Launched at Fraction of Global Price, Receives Conditional Approval for Severe GVHD
BioInformant China Overview China's first approved mesenchymal stem cell (MSC) therapy, Ruibosheng, has been launched at a fraction of global pricing, having received conditional approval from the NMPA on January 2, 2025. Approved for st... -
Fate Therapeutics Executives Sell Shares Post-FDA IND Approval for Next-Gen Autoimmune CAR-T Candidate FT839, Market Anticipates Basket Trial Success
TipRanks USA Overview Fate Therapeutics executives engaged in significant insider stock sales following news of the U.S. FDA's Investigational New Drug (IND) approval for FT839, its next-generation off-the-shelf CAR-T candidate for autoi... -
Real-World Data Evaluates Incidence and Management of Cytokine Release Syndrome and Neurotoxicity Following Axicabtagene Ciloleucel or Brexucabtagene Autoleucel CAR-T Cell Therapy Across 87 U.S. Centers
PubMed (Center for International Blood and Marrow Transplant Research) USA Overview The Center for International Blood and Marrow Transplant Research (CIBMTR) conducted a real-world data analysis of 927 B-cell malignancy patients across ... -
FDA Warns Against Unapproved Stem Cell and Exosome Therapies, Approves Products Limited to Specific Blood Disorders
The Bridge Health & Recovery USA Overview The U.S. FDA has publicly warned against clinics marketing stem cell and exosome products with false or unsubstantiated claims. Currently, FDA-approved stem cell-based products are limited, prima...
